Trishula Therapeutics, Inc.
3 known investors
Trishula Therapeutics develops cancer treatments that target immune evasion mechanisms in the tumor microenvironment. Its lead antibody, TTX-030, is in a randomized Phase 2 study for frontline metastatic pancreatic cancer after two Phase 1/1b trials in solid tumors.